Deals
Mylan to Weigh Its Options as North American Sales Plummet
- Broader generic-medicine price pressure weighs on drugmaker
- Company reins in its annual outlook as Restasis copycat stalls
A Mylan NV EpiPen allergy shot sits on display for a photograph in Princeton, Illinois.
Photographer: Daniel AckerThis article is for subscribers only.
Generic drug giant Mylan NV said that it would review its options as the company continues to grapple with declining prices for many of its products in the U.S.
Drugmakers like Mylan that produce lower-cost versions of brand-name medicines have been grappling with plummeting prices for the past two years. The company said on Wednesday that its sales fell 22 percent in North America in the second quarter, hurt by lower volumes for products including its EpiPen allergy medication.